FILING ANALYSIS · TUESDAY, NOVEMBER 10
Spero Therapeutics, Inc. SPRO — 8-K: Departure of Directors or Certain Officers
neutral
The 8-K filing appears to be a routine disclosure of a new director, Dr. Ho, with no related-party transactions or other material information that could impact the stock price. The filing is primarily comprised of XBRL taxonomy and presentation linkbase, with no quantified surprises or significant events that could move the stock beyond 1.5% in a week.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →